Abiraterone acetate plus Prednisone/Prednisolone compared with Enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: A retrospective study of real-world data (ACES).

Das, Prantik; Taylor, Sarah; Price, James; Jones, Michael; Martin-Fernandez, Cristina; Ali, Akram; Mugunthan, Thangrarajh; Mallik, Chandrani; Ward, Colin

Das, Prantik; Taylor, Sarah; Price, James; Jones, Michael; Martin-Fernandez, Cristina; Ali, Akram; Mugunthan, Thangrarajh; Mallik, Chandrani; Ward, Colin.

Afiliação

Das P; University Hospitals of Derby NHS Trust Derby UK.
Taylor S; School of Medicine University of Nottingham Derby UK.
Price J; University Hospitals of Derby NHS Trust Derby UK.
Jones M; University Hospitals of Derby NHS Trust Derby UK.
Martin-Fernandez C; University Hospitals of Derby NHS Trust Derby UK.
Ali A; Janssen-Cilag Limited High Wycombe UK.
Mugunthan T; University Hospitals of Derby NHS Trust Derby UK.
Mallik C; University Hospitals of Derby NHS Trust Derby UK.
Ward C; University Hospitals of Derby NHS Trust Derby UK.

BJUI Compass ; 1(1): 21-31, 2020 Mar.

Article em En | MEDLINE | ID: mdl-35474912

Palavras-chave

Enzalutamide; abiraterone; castrate resistant; overall survival; progression free survival; prostate cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies Idioma: En Revista: BJUI Compass Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google